Copertina

A Likelihood Perspective on Dose‐Finding Study Designs in Oncology

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Zhiwei Zhang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Pharmaceutical Statistics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A Phase I Dose‐Finding Design Incorporating Intra‐Patient Dose Escalation
di: Beibei Guo, et al.
Pubblicazione: (2024)

Reparametrized Firth's Logistic Regressions for Dose‐Finding Study With the Biased‐Coin Design
di: Hyungwoo Kim, et al.
Pubblicazione: (2024)

A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology
di: Jun Zhang, et al.
Pubblicazione: (2024)

BOIN ‐ MEM : A Two‐Stage Design for Dose Optimization With Information Borrowing Across Dose Levels and Stages in Oncology Phase I/ II Trials
di: Ryo Kitabayashi, et al.
Pubblicazione: (2025)

A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials
di: Yingjie Qiu, et al.
Pubblicazione: (2024)

A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality
di: Maxine Ajimi, et al.
Pubblicazione: (2026)

Informing the Borrowing Process for Dose‐Finding Trials by Estimating the Similarity Between Population‐Specific Dose‐Toxicity Curves
di: Dario Zocholl, et al.
Pubblicazione: (2025)

A Personalized Dose‐Finding Algorithm Based on Adaptive Gaussian Process Regression
di: Yeonhee Park, et al.
Pubblicazione: (2024)

PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose
di: Hao Sun, et al.
Pubblicazione: (2024)

Finding the Optimal Number of Splits and Repetitions in Double Cross‐Fitting Targeted Maximum Likelihood Estimators
di: Mohammad Ehsanul Karim, et al.
Pubblicazione: (2025)

Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints
di: Gina D'Angelo, et al.
Pubblicazione: (2025)

Great Wall: A Generalized Dose Optimization Design for Drug Combination Trials Maximizing Survival Benefit
di: Yan Han, et al.
Pubblicazione: (2025)

To Dilute or Not to Dilute: Nominal Titer Dosing for Genetic Medicines
di: Paul Faya, et al.
Pubblicazione: (2024)

Evaluating Safety Rules in Ongoing Dose‐Escalation Trials Using BOIN : A Comparative Analysis of Criteria and Their Impact on Dose‐Level Safety Assessments
di: Stefan Englert, et al.
Pubblicazione: (2026)

A Unified Approach to Covariate Adjustment for Survival Endpoints in Randomized Clinical Trials
di: Zhiwei Zhang, et al.
Pubblicazione: (2025)

“Within‐Trial” Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation
di: Emilie Højbjerre‐Frandsen, et al.
Pubblicazione: (2026)

A Bayesian Hybrid Design With Borrowing From Historical Study
di: Zhaohua Lu, et al.
Pubblicazione: (2024)

Information‐based group sequential design for post‐market safety monitoring of medical products using real world data
di: Zhiwei Zhang, et al.
Pubblicazione: (2024)

Control of Unconditional Type I Error in Clinical Trials With External Control Borrowing—A Two‐Stage Adaptive Design Perspective
di: Ping Gao, et al.
Pubblicazione: (2025)

Quality by Design for Preclinical In Vitro Assay Development
di: Jonathan Jones, et al.
Pubblicazione: (2024)

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio
di: David Hinds, et al.
Pubblicazione: (2024)

A Weighted Geometric Average Hazard Ratio Based Sample Size Formula for Non‐Proportional Hazards and Its Application to a Smoothed Piecewise Model in Cancer Immunotherapy Trial Design
di: Qingyang Zhang, et al.
Pubblicazione: (2025)

Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide
di: Anders Granholm, et al.
Pubblicazione: (2025)

Variable Duration Trial as an Alternative Design for Continuous Endpoints
di: Jitendra Ganju, et al.
Pubblicazione: (2024)

CUSUMIN Combination: A Cumulative Sum Interval Design for Phase I Cancer Drug‐Combination Trials
di: Tomoyoshi Hatayama, et al.
Pubblicazione: (2025)

A Flexible Seamless Phase 2/3 Design With Biomarker‐Driven Subgroup Enrichment and Sample Size Re‐Estimation
di: Zizhong Tian, et al.
Pubblicazione: (2025)

Applying the Principal Stratum Strategy in Equivalence Trials: A Case Study
di: Jerome Sepin, et al.
Pubblicazione: (2025)

Application of Causal Inference to Establish Assay Effect in the Absence of a Bridging Study: A Case Study of MenACWY ‐ CRM Conjugate Vaccine Data
di: Meike Adani, et al.
Pubblicazione: (2026)

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments
di: Derek Dinart, et al.
Pubblicazione: (2024)

Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding
di: Douglas Faries, et al.
Pubblicazione: (2024)

Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study
di: Andrea Callegaro, et al.
Pubblicazione: (2026)

Multiplicity Adjustment Methods for a Three‐Way Crossover Bioequivalence Study
di: David Hinds, et al.
Pubblicazione: (2026)

Statistical Consideration for Event‐Free Survival With Cure Rate in Acute Myeloid Leukemia Studies
di: Yuichiro Kaneko, et al.
Pubblicazione: (2025)

Extending Multiple Testing With Unknown Test Dependency via the CoCo Test: With Applications to Cancer Studies
di: Jiangtao Gou, et al.
Pubblicazione: (2025)

Simulation‐Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies
di: Chiara Micoli, et al.
Pubblicazione: (2025)

Using Propensity Score Weighting to Enhance the Operating Characteristics of Power Prior in Leveraging External Data to Augment a Traditional Clinical Study
di: Heng Li, et al.
Pubblicazione: (2025)

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
di: Konstantinos Sechidis, et al.
Pubblicazione: (2024)

Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups
di: Dan Jackson, et al.
Pubblicazione: (2024)

Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies
di: Vinicius Bonato, et al.
Pubblicazione: (2024)

A practical guide to the appropriate analysis of eGFR data over time: A simulation study
di: Todd DeVries, et al.
Pubblicazione: (2024)